The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- 15 October 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (20), 6127-6140
- https://doi.org/10.1158/1078-0432.ccr-19-0448
Abstract
Purpose: PARP inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOC). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We assessed the activity of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor known to cause replication catastrophe, as monotherapy and in combination with the PARP inhibitor olaparib in preclinical models of HGSOC, including those with acquired PARP inhibitor resistance. Experimental Design: Prexasertib was tested as a single agent or in combination with olaparib in 14 clinically annotated and molecularly characterized luciferized HGSOC patient-derived xenograft (PDX) models and in a panel of ovarian cancer cell lines. The ability of prexasertib to impair HR repair and replication fork stability was also assessed. Results: Prexasertib monotherapy demonstrated antitumor activity across the 14 PDX models. Thirteen models were resistant to olaparib monotherapy, including 4 carrying BRCA1 mutation. The combination of olaparib with prexasertib was synergistic and produced significant tumor growth inhibition in an olaparib-resistant model and further augmented the degree and durability of response in the olaparib-sensitive model. HGSOC cell lines, including those with acquired PARP inhibitor resistance, were also sensitive to prexasertib, associated with induction of DNA damage and replication stress. Prexasertib also sensitized these cell lines to PARP inhibition and compromised both HR repair and replication fork stability. Conclusions: Prexasertib exhibits monotherapy activity in PARP inhibitor–resistant HGSOC PDX and cell line models, reverses restored HR and replication fork stability, and synergizes with PARP inhibition.Keywords
Other Versions
Funding Information
- Lilly-Dana-Farber Cancer Institute Program (A09640)
- NIH (R37 HL052725, P01 HL048546, P50 CA168504)
- U.S. Department of Defense (BM110181, BC151331P1)
This publication has 49 references indexed in Scilit:
- Type-Specific Cell Line Models for Type-Specific Ovarian Cancer ResearchPLOS ONE, 2013
- The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designBritish Journal of Clinical Pharmacology, 2013
- Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1 InactivationPLOS ONE, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersNature Structural & Molecular Biology, 2010
- Fanconi anemia and breast cancer susceptibility meet againNature Genetics, 2010
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA BreaksCell, 2010
- Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and RepairMolecular Cell, 2010
- G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancerBritish Journal of Cancer, 2008
- Activation of mammalian Chk1 during DNA replication arrestThe Journal of cell biology, 2001